CN104544067A - Health food composition for preventing osteoporosis and preparation method for health food composition - Google Patents
Health food composition for preventing osteoporosis and preparation method for health food composition Download PDFInfo
- Publication number
- CN104544067A CN104544067A CN201410824520.4A CN201410824520A CN104544067A CN 104544067 A CN104544067 A CN 104544067A CN 201410824520 A CN201410824520 A CN 201410824520A CN 104544067 A CN104544067 A CN 104544067A
- Authority
- CN
- China
- Prior art keywords
- food composition
- parts
- health
- osteoporosis
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 235000013402 health food Nutrition 0.000 title claims abstract description 11
- 238000001035 drying Methods 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 235000013305 food Nutrition 0.000 claims description 30
- 230000002265 prevention Effects 0.000 claims description 28
- 239000009636 Huang Qi Substances 0.000 claims description 14
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 14
- 210000000582 semen Anatomy 0.000 claims description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 7
- 239000012567 medical material Substances 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 5
- 229940013618 stevioside Drugs 0.000 claims description 5
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 5
- 235000019202 steviosides Nutrition 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 3
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 3
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 3
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 229960004793 sucrose Drugs 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 235000012730 carminic acid Nutrition 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 229960004106 citric acid Drugs 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229960000292 pectin Drugs 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 244000077995 Coix lacryma jobi Species 0.000 abstract 2
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 2
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 2
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 2
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 2
- 241001116742 Drynaria Species 0.000 abstract 2
- 244000197580 Poria cocos Species 0.000 abstract 2
- 235000008599 Poria cocos Nutrition 0.000 abstract 2
- 244000046146 Pueraria lobata Species 0.000 abstract 2
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 2
- 235000006533 astragalus Nutrition 0.000 abstract 2
- 238000005303 weighing Methods 0.000 abstract 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 24
- 210000000988 bone and bone Anatomy 0.000 description 18
- 239000013641 positive control Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 9
- 102000008108 Osteoprotegerin Human genes 0.000 description 7
- 108010035042 Osteoprotegerin Proteins 0.000 description 7
- 108010025832 RANK Ligand Proteins 0.000 description 7
- 102000014128 RANK Ligand Human genes 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 7
- 210000004291 uterus Anatomy 0.000 description 7
- 210000002997 osteoclast Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000000689 upper leg Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 230000018044 dehydration Effects 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 5
- 210000000963 osteoblast Anatomy 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- -1 antiseptic Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 101100537826 Rattus norvegicus Tnfrsf11b gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a health food composition for preventing osteoporosis. The health food composition is prepared from the following raw materials in parts by weight: 3-15 parts of drynaria rhizome, 9-30 parts of astragalus membranaceus, 9-15 parts of roots of kudzu vine, 9-15 parts of poria cocos, 3-10 parts of rhizoma curcumae longae, 9-30 parts of Chinese yam and 9-30 parts of coix seeds. A preparation method for the health food composition comprises the following steps: weighing the roots of kudzu vine, the poria cocos, the rhizoma curcumae longae, the Chinese yam and the coix seeds in parts by weight, and crushing into raw powder after drying and dehydrating; weighing the drynaria rhizome and the astragalus in parts by weight, decocting with water, concentrating into paste, drying and crushing; uniformly mixing the raw powder and dry extract powder, and adding auxiliary materials to prepare the health food preparation. The health food composition for preventing osteoporosis provided by the invention has the characteristics of being reasonable in price, remarkable in effect and free of toxic or side effect.
Description
Technical field
The invention belongs to field of health care food, be specifically related to a kind of health-care food composition of prevention of osteoporosis and the preparation method of this health-care food composition.
Background technology
Osteoporosis is that bone amount reduces, and bone strength reduces and causes the clinical syndrome of limitation osteodynia, deformity and fracture.It is relevant that morbidity and endocrine regulation, calcium absorption are bad etc., has dividing of constitutional and Secondary cases.How osteoporosis insidious onset, once find, developed into a certain degree.Increase with the age, bone loss and incidence of fracture obviously increase.Osteoporotic fracture can occur in any position, but common with vertebra, wrist and hip.Hip Fracture is the most serious, need surgical procedure, and patient often merges chronic disease more, and as hypertension, cardiovascular, chronic obstructive airway disease and diabetes etc., cause medical expense and mortality rate to increase, quality of life declines.
Osteoporosis is one of disease that sickness rate, mortality rate and health care consumption are larger in the world at present.Especially postmenopausal osteoporosis is modal primary osteoporosis, sickness rate is high, in recent years along with social senilization, the prolongation of population life, women's post menopausal existence time limit accounts for 1/3 of all one's life, in primary osteoporosis and the fracture serious threat that causes thereof, old women is healthy, and become mondial serious society and economic problems, therefore osteoporotic prevention is most important.
Modern medicine is thought, osteoporosis occurs with hormone regulating and controlling, immunologic function, living habit etc. closely related.Wherein ovarian failure, estrogen secretion deficiency be up to now most study, understand one of the darkest field.
The tcm theory of health care then thinks that osteoporosis is many will need nourish the day after tomorrow because of congenital essence, and kidney deficiency then spleen is not good for, and suffer from a deficiency of the kidney simultaneously with insufficiency of the spleen, healthy energy virtual loss, exopathogen invades bone in an opponent's defence deeply, and QI-blood circulation is smooth, the stagnant venation of the stasis of blood, bone become homeless foster caused by.Therefore emphasize based on the kidney invigorating and essence nourishing, be aided with strengthening spleen and nourishing blood, blood circulation promoting and blood stasis dispelling, bone and muscle strengthening.
Doctor trained in Western medicine many employings estrogen replacement therapy method, but this method can have harmful effect to other target organs such as mammary gland and uterus etc., increase the risk of carcinoma of endometrium and breast carcinoma, and cause coronary heart disease, cerebral thrombosis, cholecystitis etc., therefore in use, be subject to a definite limitation.And other treatment means also exist some problems, late result is uncertain, expensive, and calcium preparation absorption is not good, and application stage by stage clinically, and patient often can not grasp and adhere to, compliance is poor, and therapeutical effect is greatly reduced.
Summary of the invention
The object of the present invention is to provide a kind of reasonable price, Be very effective, the health-care food composition of the prevention of osteoporosis had no side effect,
Another object of the present invention is to the preparation method of the health-care food composition that this prevention of osteoporosis is provided.
The health-care food composition of a kind of prevention of osteoporosis of the present invention, by weight, comprises following raw material:
Rhizoma Drynariae 3-15 part, Radix Astragali 9-30 part, Radix Puerariae 9-15 part, Poria 9-15 part, Rhizoma Curcumae Longae 3-10 part, Rhizoma Dioscoreae 9-30 part, Semen Coicis 9-30 part.
The health-care food composition of a kind of prevention of osteoporosis of the present invention, by weight, comprises following raw material:
Rhizoma Drynariae 8-12 part, Radix Astragali 15-25 part, Radix Puerariae 10-14 part, Poria 10-14 part, Rhizoma Curcumae Longae 6-9 part, Rhizoma Dioscoreae 15-25 part, Semen Coicis 15-25 part.
The health-care food composition of a kind of prevention of osteoporosis of the present invention, by weight, comprises following raw material:
Rhizoma Drynariae 9 parts, the Radix Astragali 20 parts, Radix Puerariae 12 parts, 12 parts, Poria, 7 parts, Rhizoma Curcumae Longae, Rhizoma Dioscoreae 23 parts, Semen Coicis 20 parts.
The health-care food composition of a kind of prevention of osteoporosis of the present invention, wherein, described Rhizoma Dioscoreae is Rhizoma Dioscoreae.
The preparation method of the health-care food composition of a kind of prevention of osteoporosis of the present invention, comprises the following steps:
(1) take Radix Puerariae, Poria, Rhizoma Curcumae Longae, Rhizoma Dioscoreae and Semen Coicis by weight, after frozen drying or the dehydration of vacuum and low temperature microwave drying, be ground into fecula, for subsequent use;
(2) Rhizoma Drynariae and the Radix Astragali is taken by weight, with medical material total amount 6-8 times soak by water three times, first time 2h, second time 1.5h, third time 1h, collecting decoction, filters, and filtrate is concentrated into that temperature is 60 DEG C, relative density is the extractum of 1.17-1.35, dry, pulverize;
(3) fecula obtained in step (1) is mixed with the dry extract in step (2), add adjuvant and make health food preparation and get final product.
The preparation method of the health-care food composition of a kind of prevention of osteoporosis of the present invention, wherein, drying described in step (1) is frozen drying or vacuum and low temperature microwave drying.
The preparation method of the health-care food composition of a kind of prevention of osteoporosis of the present invention, wherein, described health food preparation comprises tablet, pill, powder, capsule, granule, oral liquid, powder.
The preparation method of the health-care food composition of a kind of prevention of osteoporosis of the present invention, wherein, described adjuvant comprises magnesium stearate, dextrin, crospolyvinylpyrrolidone, stevioside, sucrose, Butylated hydroxyanisole, microcrystalline Cellulose, starch, pectin, carrageenan, xylitol, citric acid, carmine; Other disintegrating agents can also be comprised, lubricant, filler, thickening agent, binding agent, acidity regulator, sweeting agent, antiseptic, coloring agent, enzyme preparation etc.
The health-care food composition of a kind of prevention of osteoporosis of the present invention, wherein, described Rhizoma Drynariae, the Radix Astragali, Radix Puerariae, Poria, Rhizoma Curcumae Longae, Rhizoma Dioscoreae, Semen Coicis are " Chinese Pharmacopoeia " (2010 editions) first Chinese medicine recorded or processed products.
The present invention compared with prior art, there is obvious beneficial effect, as can be known from the above technical solutions: health-care food composition provided by the present invention, use traditional Chinese medical science compatibility theory, there is warming and recuperating the kidney-YANG, strong muscles and bones, tonification invigorate blood circulation, nourish congenital essence, to supplement nutrition the effect of bone marrow, can bone cell proliferation be stimulated, suppress differentiation of osteoclast, promoting bone growing, reduce bone high-conversion rate, effective raising bone density, and can microcirculation be improved, maintain bone metabolism balance, correct bone structure, thus prevent developing of osteoporosis.It selects integration of edible and medicinal herbs raw material, has that toxic and side effects is little, reasonable price, and treating both the principal and secondary aspects of a disease also can the advantage of long-term taking.
Detailed description of the invention
The beneficial effect of medicine of the present invention is set forth further below by way of experimental example.
experimental example
The experiment of osteoporosis drug effect is carried out with the embodiment of the present invention 2 gained capsule
1. laboratory animal: SD female rats, SPF level, body weight 200-250g, the animal quality certification number: SCXK(change) 2012-0005.
2. rearing conditions: animal is by special messenger's feeding and management, and point cage is fed, single only single cage.Normal rats feedstuff.Laboratory illumination is sufficient, well-ventilated, room temperature 18-26 DEG C, humidity 40-70%.
3. model rat with osteoporosis is set up: adapt to feeding after 2 weeks, with Nembutal sodium solution, by 0.3ml/100g body weight intraperitoneal injection of anesthesia, get ventricumbent position, wipe out and become mildewed, routine disinfection, midline incision, spay, spreads with penicillin powder, sews up, lateral recumbent posture is taked to put back in cage, normal water, sham operated rats is carried out with same steps, but not spay.
4. laboratory animal grouping and administration: after rat operation rehabilitation, grouping, sham operated rats is 10, ovariectomized female rats is divided into 5 groups at random, i.e. model control group, positive controls, and test high, medium and low dosage group, often group is 10.Another name gets the preparation obtained in above-described embodiment, be made into 12.5mg/ml, 25mg/ml, 50mg/ml strength solution, gives corresponding dosage treated animal gavage respectively, and gavage volume is 0.2mL/10g BW, sham operated rats and model group give isopyknic normal saline, positive controls gives bone pine and protects capsule 209.9mg/kg.bw, every day gavage 1 time, continuous gavage 90 days.
5. method of drawing material: the equal fasting 12h of each group rat before drawing materials, freely drinks water.With Nembutal sodium solution (0.3ml/kg.bw) intraperitoneal injection of anesthesia, extract eyeball and get blood, centrifuging and taking serum, detect osteoprotegerin (OPG) and receptor activator of the nuclear factor-κappaB ligand (RANKL) level in serum with test kit, the results are shown in Table 1.Extract uterus and weigh, the results are shown in Table 2.Peel off bilateral femur, examine in 105 DEG C of baking boxs to constant weight, measure left femur bone density with dual intensity X-ray borne densitometers, the results are shown in Table 3.Get right side femur, do paraffin section with the decalcification of neutral disodiumedetate decalcifying Fluid after two weeks, HE dyes, and observes osteoblast number, osteoclast number, bone trabecula thickness, bone trabecula gap, the results are shown in Table 4 under microscope.
Table 1 the present invention is on OPG and RANKL level impact (x ± s) in serum
| Group | Animal number of elements | OPG（ng/L） | RANKL（nmol/L） |
| Sham operated rats | 10 | 118.500±7.703 ** | 0.040±0.003 ** |
| Model group matched group | 10 | 88.167±7.710 | 0.056±0.004 |
| Positive controls | 10 | 99.000±7.120 ** | 0.045±0.004 ** |
| High dose group of the present invention | 10 | 109.869±6.342 ** | 0.042±0.003 ** |
| Dosage group in the present invention | 10 | 105.000±5.449 ** | 0.047±0.002 ** |
| Low dose group of the present invention | 10 | 98.167±6.831 ** | 0.052±0.004 * |
Note: compare with model control group, * is P<0.05, * * is P<0.01
As seen from Table 1: contrast with normal group, model group rats OPG level significantly improves, and have statistical significance (P<0.01), RANKL level significantly reduces (P<0.01), reminds modeling success; Contrast with model group, positive controls, the present invention's high, medium and low dosage group rat OPG level significantly improve (P<0.01), and RANKL level reduces, and has statistical significance (P<0.05).Illustrate that the present invention effectively can improve the content of OPG in rat blood serum, reduce RANKL content, but low dose group effect of the present invention is not as good as positive controls.
Table 2 the present invention is on the impact (x ± s) of uterus and organ index
| Group | Animal number of elements (only) | Uterus index (g/g) | Liver index (g/g) | Renal index (g/g) | Index and spleen index (g/g) |
| Sham operated rats | 10 | 0.0024±0.0006 ** | 0.0340±0.0064 | 0.0027±0.0003 | 0.0016±0.0002 |
| Model control group | 10 | 0.0008±0.0013 | 0.0305±0.0038 | 0.0026±0.0004 | 0.0015±0.0003 |
| Positive controls | 10 | 0.0016±0.0014 ** | 0.0290±0.0031 # | 0.0024±0.0002 | 0.0015± 0.0003 |
| High dose group of the present invention | 10 | 0.0021±0.0007 ** | 0.0328±0.0039 | 0.0027±0.0001 | 0.0016±0.0002 |
| Dosage group in the present invention | 10 | 0.0018±0.0018 ** | 0.0311±0.0046 | 0.0026±0.0003 | 0.0015±0.0003 |
| Low dose group of the present invention | 10 | 0.0014±0.0012 ** | 0.0298±0.0042 | 0.0025±0.0003 | 0.0015±0.0002 |
Note: compare with model control group, * is P<0.05, * * is P<0.01; Compare with sham operated rats, # is P<0.05, ## is P<0.01
As seen from Table 2: respectively organize uterus index, removal ovary is after 120 days, model group uterus severe atrophy, through administration in 90 days, positive controls and each dosage group of the present invention all have remarkable effect to maintenance uterus weight, compare difference with model group and have statistical significance, the effect of the present invention's middle and high dosage group is better than positive controls.
The present invention respectively organizes organ index and sham operated rats there was no significant difference, and preliminary judgement the present invention each dosage group is to the equal free of toxic effects of rat.
Table 3 the present invention is on the impact (x ± s) of rat femur weight and femoral bmd
| Group | Number of animals (only) | Femur weight (g) | Femoral bmd (g/cm 2) |
| Sham operated rats | 10 | 0.641±0.03 | 0.232±0.006** |
| Model control group | 10 | 0.613±0.03 | 0.197±0.012 |
| Positive controls | 10 | 0.627±0.05 | 0.217±0.008** |
| High dose group of the present invention | 10 | 0.635±0.04 | 0.219±0.011** |
| Dosage group in the present invention | 10 | 0.628±0.03 | 0.217±0.006** |
| Low dose group of the present invention | 10 | 0.612±0.02 | 0.213±0.013* |
Note: compare with model control group, * is P<0.05, * * is P<0.01
As seen from Table 3: rats in sham-operated group femoral bmd, higher than model control group (P<0.01), represents that removing ovary can cause rat bone density low; The femoral bmd of each dosage group of the present invention and positive controls rat, all higher than model control group, has statistical significance; Difference not statistically significant between each group of femur weight.Illustrate that the present invention can increase the thighbone density of ovariectomized female rats.
Table 4 the present invention is on rat bone tissue morphometry impact (x ± s)
| Group | Number of animals (only) | Bone trabecula thickness (μm) | Bone trabecula gap (μm) | Osteoblast number (individual) | Osteoclast number (individual) |
| Sham operated rats | 10 | 27.92±7.50 ** | 11.30±4.71 ** | 93±2.78 ** | 1±0.58 ** |
| Model control group | 10 | 7.44±3.57 | 29.62±4.88 | 38±2.74 | 3±0.45 |
| Positive controls | 10 | 18.78±2.43 ** | 19.76±3.98 * | 65±4.42 ** | 2±0.13 * |
| High dose group of the present invention | 10 | 24.59±2.76 ** | 15.43±4.32 ** | 79±2.56 ** | 1±0.31 ** |
| Dosage group in the present invention | 10 | 18.67±2.68 ** | 20.22±1.92 * | 64±5.09 ** | 2±0.18 * |
| Low dose group of the present invention | 10 | 15.33±3.14 * | 23.36±4.33 | 48±4.45 * | 2±0.67 |
Note: compare with model control group, * is P<0.05, * * is P<0.01
From table 4: compare with normal group, model control group bone trabecula thickness reduces, and the broadening osteoclast digital display work in gap increases, and osteoblast digital display work reduces, and shows that oophorectomize causes bone resorption to increase, display modeling success; Compare with model control group, positive controls, the present invention's each dosage group bone trabecula thickness all obviously increase, and bone trabecula gap is obviously lowered, osteoblast digital display work increases, osteoclast number obviously reduces (P<0.05), and high dose group effect of the present invention stronger (P<0.01).The each index of Trabecular area that the present invention can reverse caused by oophorectomize changes.
This experimental result shows that health-care food composition of the present invention is by the dual function promoting the secretion of osteoblast osteoprotegerin and suppress RANKL to express; suppress the function of osteoclast; and affect each index parameter of bone histomorphometric, thus reach the effect of prevention of osteoporosis.
embodiment 1
A health-care food composition for prevention of osteoporosis, comprises the following steps:
(1) take Radix Puerariae 9g, Poria 9g, Rhizoma Curcumae Longae 3g, Rhizoma Dioscoreae 9g, Semen Coicis 9g, after frozen drying dehydration, be ground into fecula, for subsequent use;
(2) Rhizoma Drynariae 3g is taken, Radix Astragali 9g, with medical material total amount 7 times of soak by water three times, first time 2h, second time 1.5h, third time 1h, collecting decoction, filters, and filtrate is concentrated into that temperature is 60 DEG C, relative density is the extractum of 1.23, dry, pulverize;
(3) fecula obtained in step (1) is mixed with the dry extract in step (2), add dextrin, magnesium stearate, crospolyvinylpyrrolidone, stevioside, evenly granulate, tabletting.
embodiment 2
A health-care food composition for prevention of osteoporosis, comprises the following steps:
(1) take Radix Puerariae 15g, Poria 15g, Rhizoma Curcumae Longae 10g, Rhizoma Dioscoreae 30g, Semen Coicis 30g, after the dehydration of vacuum and low temperature microwave drying, superfine powder is broken into fecula, for subsequent use;
(2) Rhizoma Drynariae 15g is taken, Radix Astragali 30g, with medical material gross weight 6 times of soak by water three times, first time 2h, second time 1.5h, third time 1h, collecting decoction, filters, and filtrate is concentrated into that temperature is 60 DEG C, relative density is the extractum of 1.17, dry, pulverize;
(3) fecula obtained in step (1) is mixed with the dry extract in step (2), add dextrin, magnesium stearate, Homogeneous phase mixing, encapsulated.
embodiment 3
A health-care food composition for prevention of osteoporosis, comprises the following steps:
(1) take Radix Puerariae 12g, Poria 12g, Rhizoma Curcumae Longae 7g, Rhizoma Dioscoreae 23g, Semen Coicis 20g, after frozen drying dehydration, superfine powder is broken into fecula, for subsequent use;
(2) Rhizoma Drynariae 9g is taken, Radix Astragali 20g, with medical material gross weight 6 times of soak by water three times, first time 2h, second time 1.5h, third time 1h, collecting decoction, filters, and filtrate is concentrated into that temperature is 60 DEG C, relative density is the extractum of 1.30, dry, pulverize;
(3) fecula obtained in step (1) is mixed with the extract dry powder in step (2), add dextrin, magnesium stearate, stevioside or sucrose, Homogeneous phase mixing, routinely technique granule.
embodiment 4
A health-care food composition for prevention of osteoporosis, comprises the following steps:
(1) take Radix Puerariae 10g, Poria 14g, Rhizoma Curcumae Longae 6g, Rhizoma Dioscoreae 25g, Semen Coicis 25g, after frozen drying dehydration, superfine powder is broken into fecula, for subsequent use;
(2) Rhizoma Drynariae 8g is taken, Radix Astragali 25g, with medical material gross weight 8 times of soak by water three times, first time 2h, second time 1.5h, third time 1h, collecting decoction, filters, and filtrate is concentrated into that temperature is 60 DEG C, relative density is the extractum of 1.27, dry, pulverize;
(3) fecula obtained in step (1) is mixed with the dry extract in step (2), add stevioside or sucrose, Butylated hydroxyanisole, microcrystalline Cellulose, Homogeneous phase mixing, routinely technique powder process agent.
embodiment 5
A health-care food composition for prevention of osteoporosis, comprises the following steps:
(1) take Radix Puerariae 14g, Poria 10g, Rhizoma Curcumae Longae 9g, Rhizoma Dioscoreae 15g, Semen Coicis 15g, after drying and dehydrating, superfine powder is broken into fecula, for subsequent use;
(2) Rhizoma Drynariae 12g is taken, Radix Astragali 15g, with medical material gross weight 8 times of soak by water three times, first time 2h, second time 1.5h, third time 1h, collecting decoction, filters, and filtrate is concentrated into that temperature is 60 DEG C, relative density is the extractum of 1.35, dry, pulverize;
(3) fecula obtained in step (1) is mixed with the dry extract in step (2), add dextrin, magnesium stearate, microcrystalline Cellulose, Homogeneous phase mixing, routinely the agent of technique pill.
The above, it is only preferred embodiment of the present invention, not any pro forma restriction is done to the present invention, anyly do not depart from technical solution of the present invention content, the any simple modification done above embodiment according to technical spirit of the present invention, equivalent variations and modification, all still belong in the scope of technical solution of the present invention.
Claims (8)
1. a health-care food composition for prevention of osteoporosis, by weight, comprises following raw material: Rhizoma Drynariae 3-15 part, Radix Astragali 9-30 part, Radix Puerariae 9-15 part, Poria 9-15 part, Rhizoma Curcumae Longae 3-10 part, Rhizoma Dioscoreae 9-30 part, Semen Coicis 9-30 part.
2. the health-care food composition of a kind of prevention of osteoporosis as claimed in claim 1, is characterized in that: by weight, comprises following raw material: Rhizoma Drynariae 8-12 part, Radix Astragali 15-25 part, Radix Puerariae 10-14 part, Poria 10-14 part, Rhizoma Curcumae Longae 6-9 part, Rhizoma Dioscoreae 15-25 part, Semen Coicis 15-25 part.
3. the health-care food composition of a kind of prevention of osteoporosis as claimed in claim 1, is characterized in that: by weight, comprises following raw material: Rhizoma Drynariae 9 parts, the Radix Astragali 20 parts, Radix Puerariae 12 parts, 12 parts, Poria, 7 parts, Rhizoma Curcumae Longae, Rhizoma Dioscoreae 23 parts, Semen Coicis 20 parts.
4. the health-care food composition of a kind of prevention of osteoporosis as described in one of claim 1 or 2 or 3, is characterized in that: described Rhizoma Dioscoreae is Rhizoma Dioscoreae.
5. the preparation method of the health-care food composition of a kind of prevention of osteoporosis as described in one of claim 1 or 2 or 3, comprises the following steps:
(1) take Radix Puerariae, Poria, Rhizoma Curcumae Longae, Rhizoma Dioscoreae and Semen Coicis by weight, after drying and dehydrating, be ground into fecula, for subsequent use;
(2) Rhizoma Drynariae and the Radix Astragali is taken by weight, with medical material total amount 6-8 times soak by water three times, first time 2h, second time 1.5h, third time 1h, collecting decoction, filters, and filtrate is concentrated into that temperature is 60 DEG C, relative density is the extractum of 1.17-1.35, dry, pulverize;
(3) fecula obtained in step (1) is mixed with the dry extract in step (2), add adjuvant and make health food preparation and get final product.
6. the preparation method of the health-care food composition of a kind of prevention of osteoporosis as claimed in claim 5, is characterized in that: dry described in step (1) is frozen drying or vacuum and low temperature microwave drying.
7. the preparation method of the health-care food composition of a kind of prevention of osteoporosis as claimed in claim 5, is characterized in that: described health food preparation comprises tablet, pill, powder, capsule, granule, oral liquid, powder.
8. according to the preparation method of the health-care food composition of a kind of prevention of osteoporosis according to claim 5, it is characterized in that: described adjuvant comprises magnesium stearate, dextrin, crospolyvinylpyrrolidone, stevioside, sucrose, Butylated hydroxyanisole, microcrystalline Cellulose, starch, pectin, carrageenan, xylitol, citric acid, carmine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410824520.4A CN104544067B (en) | 2014-12-26 | 2014-12-26 | Health food composition for preventing osteoporosis and preparation method for health food composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410824520.4A CN104544067B (en) | 2014-12-26 | 2014-12-26 | Health food composition for preventing osteoporosis and preparation method for health food composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104544067A true CN104544067A (en) | 2015-04-29 |
| CN104544067B CN104544067B (en) | 2017-01-11 |
Family
ID=53061989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410824520.4A Active CN104544067B (en) | 2014-12-26 | 2014-12-26 | Health food composition for preventing osteoporosis and preparation method for health food composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104544067B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106177908A (en) * | 2015-05-06 | 2016-12-07 | 北京宝德润生医药科技发展有限公司 | A kind of have compositions increasing bone substance density improving function and preparation method thereof |
| CN110384229A (en) * | 2018-04-18 | 2019-10-29 | 雅安迅康药业有限公司 | A kind of health-care food composition and application thereof increasing bone density |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1666764A (en) * | 2004-03-09 | 2005-09-14 | 江苏康缘药业股份有限公司 | Fracture union-promoting medicine and its preparation |
| CN101129448A (en) * | 2006-08-21 | 2008-02-27 | 香港科技大学 | Compositions for preventing and controlling climacteric syndrome and osteoporosis, and processes for producing the same |
| CN101485722A (en) * | 2009-02-13 | 2009-07-22 | 南京师范大学 | Medicament composition containing drynaria and salvia root, and use thereof |
| CN101856114A (en) * | 2010-05-14 | 2010-10-13 | 浙江省医学科学院 | Health food with bone intensity enhancing function and preparation method thereof |
| CN103316143A (en) * | 2013-07-02 | 2013-09-25 | 上海市长宁区光华中西医结合医院 | Chinese medicine composition for inhibiting rheumatoid arthritis inflammation and reducing bone mass loss and application thereof |
-
2014
- 2014-12-26 CN CN201410824520.4A patent/CN104544067B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1666764A (en) * | 2004-03-09 | 2005-09-14 | 江苏康缘药业股份有限公司 | Fracture union-promoting medicine and its preparation |
| CN101129448A (en) * | 2006-08-21 | 2008-02-27 | 香港科技大学 | Compositions for preventing and controlling climacteric syndrome and osteoporosis, and processes for producing the same |
| CN101485722A (en) * | 2009-02-13 | 2009-07-22 | 南京师范大学 | Medicament composition containing drynaria and salvia root, and use thereof |
| CN101856114A (en) * | 2010-05-14 | 2010-10-13 | 浙江省医学科学院 | Health food with bone intensity enhancing function and preparation method thereof |
| CN103316143A (en) * | 2013-07-02 | 2013-09-25 | 上海市长宁区光华中西医结合医院 | Chinese medicine composition for inhibiting rheumatoid arthritis inflammation and reducing bone mass loss and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 朱慧锋等: "骨碎补研究进展", 《中国骨伤》 * |
| 莫新民等: "中医药治疗骨质疏松症的研究进展", 《湖南中医学院学报》 * |
| 顾敏等: "骨碎补治疗原发性骨质疏松症", 《中国康复》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106177908A (en) * | 2015-05-06 | 2016-12-07 | 北京宝德润生医药科技发展有限公司 | A kind of have compositions increasing bone substance density improving function and preparation method thereof |
| CN110384229A (en) * | 2018-04-18 | 2019-10-29 | 雅安迅康药业有限公司 | A kind of health-care food composition and application thereof increasing bone density |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104544067B (en) | 2017-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103340341B (en) | Functional food with bone strengthening effect and preparation method thereof | |
| CN101284105A (en) | Thrombolysis lipid-lowering pellet for curing cardio-cerebrovascular disease | |
| CN104127861B (en) | A kind of have pharmaceutical composition increasing bone density effect and preparation method thereof | |
| CN101612279B (en) | Chinese medicine preparation for promoting fracture healing | |
| CN104544067B (en) | Health food composition for preventing osteoporosis and preparation method for health food composition | |
| CN104825528A (en) | Composition capable of increasing bone mineral density, and preparation method and application thereof | |
| CN101361930B (en) | Male sexual function tonification health product and preparation method thereof | |
| CN104225067B (en) | Chinese medicine composition, preparation method and purposes for treating postmenopausal osteoporosis | |
| CN102145118A (en) | Morinda officinalis wine | |
| CN1322888C (en) | Medicine for treating osteoporosis and its preparing method and use | |
| CN102600335B (en) | Traditional Chinese medicine for treating postpartum hypogalactia | |
| CN101843668B (en) | Chinese medicinal granules for treating femoral head necrosis and preparation method thereof | |
| CN104524524B (en) | Medicine treating osteoporosis and preparing method | |
| CN107812039A (en) | A kind of beautiful millettia root Chinese medicine composition with function of reinforcing the kidney to strengthen the bone and preparation method thereof | |
| CN106860656A (en) | It is a kind of to treat Chinese medicine composition of osteoporosis and its preparation method and application | |
| CN101934046B (en) | Semifluid extract of deer foetus and preparation method thereof | |
| CN102048145A (en) | Health food for treating hypertension in auxiliary mode and preparation method thereof | |
| CN109381491A (en) | A kind of composition and its preparation method and application for preventing and treating osteoporosis | |
| CN103169837B (en) | Composition for preventing osteoporosis | |
| CN104623544A (en) | Traditional Chinese medicine preparation capable of tonifying spleen and eliminating dampness for treating moderate fatty liver and preparation method of traditional Chinese medicine preparation | |
| CN103251935A (en) | Medicinal composite containing cornu cervi pantotrichum and application thereof | |
| CN105381168B (en) | A kind of Yaotongning medicine and preparation method thereof | |
| CN105726979A (en) | New application of Mongolian medicine compound preparation conic-gymnadenia-tuber, radix-polygonati-officinalis and rhizome-polygonati medicine and medicinal preparation and preparing method of Mongolian medicine compound preparation | |
| CN105232642A (en) | Traditional Chinese medicine combination capable of promoting fracture healing | |
| CN105213793A (en) | Cure mainly osteoporotic Chinese medicine composition and method for making |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 551400 high tech industry planning area, Qingzhen City, Guiyang City, Guizhou Province Patentee after: Guizhou Kehui Pharmaceutical Co.,Ltd. Address before: No. 17, Nanchong Lane, Jiefang West Road, Nanming District, Guiyang City, Guizhou Province, 551400 Patentee before: GUIZHOU PROVINCE KEHUI PHARMACEUTICAL FACTORY |
|
| CP03 | Change of name, title or address |